Daclatasvir for the treatment of chronic hepatitis C

@article{Degasperi2015DaclatasvirFT,
  title={Daclatasvir for the treatment of chronic hepatitis C},
  author={E. Degasperi and A. Aghemo and M. Colombo},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2679 - 2688}
}
Introduction: Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangenotypic activity and low-moderate barrier to resistance suitable for IFN-free combination with other direct acting antivirals (DAAs). Areas covered: The present review summarizes… Expand
7 Citations

References

SHOWING 1-10 OF 67 REFERENCES
NS5A inhibitors in the treatment of hepatitis C.
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
  • R. Fontana, E. Hughes, +4 authors W. Symonds
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2013
...
1
2
3
4
5
...